Reported 1 day ago
Summit Therapeutics Inc. (SMMT) saw its share price jump by 18.88% last week, closing at $27.9 after investor optimism fueled by a bullish outlook from Cantor Fitzgerald, despite a widening net loss. The company's promising ivonescimab antibody for cancer treatment received approval in China, paving the way for international expansion. Overall, SMMT ranked as the sixth best performing mid-cap stock last week, amidst an optimistic market environment bolstered by corporate earnings.
Source: YAHOO